BNP Paribas Asset Management
WST icon

BNP Paribas Asset Management’s West Pharmaceutical WST Stock Holding History

BNP Paribas Asset Management’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53.8M Buy
149,862
+104,935
+234% +$32.1M 0.05% 317
2026
Q1 		$11.3M Sell
44,927
-1,799
-4% -$448K 0.01% 666
2025
Q4 		$12.9M Sell
46,726
-42,677
-48% -$11.7M 0.01% 632
2025
Q3 		$23.4M Buy
89,403
+38,067
+74% +$9.25M 0.06% 312
2025
Q2 		$11.2M Sell
51,336
-7,581
-13% -$1.62M 0.03% 438
2025
Q1 		$13.2M Buy
58,917
+19,649
+50% +$5.42M 0.04% 402
2024
Q4 		$12.9M Sell
39,268
-6,956
-15% -$2.19M 0.03% 414
2024
Q3 		$13.9M Sell
46,224
-3,317
-7% -$1.02M 0.03% 382
2024
Q2 		$16.3M Sell
49,541
-8,159
-14% -$2.88M 0.04% 334
2024
Q1 		$22.8M Sell
57,700
-40,348
-41% -$14.9M 0.06% 284
2023
Q4 		$34.5M Buy
98,048
+6,395
+7% +$2.26M 0.1% 234
2023
Q3 		$34.4M Buy
91,653
+2,065
+2% +$799K 0.11% 214
2023
Q2 		$34.3M Buy
89,588
+5,344
+6% +$1.91M 0.11% 211
2023
Q1 		$29.2M Sell
84,244
-22,825
-21% -$6.67M 0.1% 220
2022
Q4 		$25.2M Buy
107,069
+3,548
+3% +$841K 0.09% 259
2022
Q3 		$25.5M Buy
103,521
+14,154
+16% +$4.31M 0.1% 233
2022
Q2 		$27M Sell
89,367
-10,203
-10% -$3.32M 0.1% 224
2022
Q1 		$40.9M Sell
99,570
-9,387
-9% -$3.67M 0.14% 179
2021
Q4 		$51.1M Buy
108,957
+39,663
+57% +$17.1M 0.17% 142
2021
Q3 		$29.4M Buy
69,294
+1,339
+2% +$564K 0.11% 221
2021
Q2 		$24.4M Buy
67,955
+30,597
+82% +$10.1M 0.09% 270
2021
Q1 		$10.5M Sell
37,358
-628
-2% -$180K 0.04% 405
2020
Q4 		$10.8M Buy
37,986
+1,599
+4% +$449K 0.05% 371
2020
Q3 		$10M Buy
36,387
+6,476
+22% +$1.71M 0.06% 324
2020
Q2 		$6.79M Buy
29,911
+6,615
+28% +$1.3M 0.05% 373
2020
Q1 		$3.55M Buy
23,296
+2,628
+13% +$405K 0.03% 461
2019
Q4 		$3.11M Buy
+20,668
New +$3.01M 0.02% 549

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BNP Paribas Asset Management's WST Position: Q2 2026 in Review

BNP Paribas Asset Management increased its West Pharmaceutical (WST) stake by 234% in Q2 2026, buying an estimated $32.1M and bringing the position to 149,862 shares worth $53.8M. The position accounts for 0.05% of the portfolio, ranked #317.

BNP Paribas Asset Management first reported a position in WST in Q4 2019 and has held it in 27 quarters since. 834 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • BNP Paribas Asset Management held 149,862 shares of West Pharmaceutical worth $53.8M as of Q2 2026.
  • BNP Paribas Asset Management bought 104,935 West Pharmaceutical shares in Q2 2026, an estimated $32.1M.
  • West Pharmaceutical made up 0.05% of BNP Paribas Asset Management's portfolio in Q2 2026, its #317 holding.
  • BNP Paribas Asset Management first reported a position in West Pharmaceutical in Q4 2019 and has held it in 27 quarters since.
  • 834 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.